

# Nazha Hamdani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3857508/publications.pdf>

Version: 2024-02-01

102  
papers

6,415  
citations

76294

40  
h-index

69214

77  
g-index

104  
all docs

104  
docs citations

104  
times ranked

7337  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diastolic Stiffness of the Failing Diabetic Heart. <i>Circulation</i> , 2008, 117, 43-51.	1.6	621
2	Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2012, 126, 830-839.	1.6	418
3	Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 312-324.	1.9	390
4	Hypophosphorylation of the Stiff N2B Titin Isoform Raises Cardiomyocyte Resting Tension in Failing Human Myocardium. <i>Circulation Research</i> , 2009, 104, 780-786.	2.0	318
5	Gigantic Business. <i>Circulation Research</i> , 2014, 114, 1052-1068.	2.0	288
6	Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. <i>Nature</i> , 2015, 519, 472-476.	13.7	274
7	Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model. <i>Circulation: Heart Failure</i> , 2013, 6, 1239-1249.	1.6	241
8	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	1.0	195
9	Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2013, 97, 464-471.	1.8	191
10	S-Glutathionylation of Cryptic Cysteines Enhances Titin Elasticity by Blocking Protein Folding. <i>Cell</i> , 2014, 156, 1235-1246.	13.5	170
11	Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G $\pm$ oxidation. <i>Cardiovascular Research</i> , 2021, 117, 495-507.	1.8	167
12	Empagliflozin directly improves diastolic function in human heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1690-1700.	2.9	165
13	Sildenafil and B-Type Natriuretic Peptide Acutely Phosphorylate Titin and Improve Diastolic Distensibility In Vivo. <i>Circulation</i> , 2011, 124, 2882-2891.	1.6	162
14	Crucial Role for Ca <sup>2+</sup> /Calmodulin-Dependent Protein Kinase-II in Regulating Diastolic Stress of Normal and Failing Hearts via Titin Phosphorylation. <i>Circulation Research</i> , 2013, 112, 664-674.	2.0	160
15	Sarcomeric dysfunction in heart failure. <i>Cardiovascular Research</i> , 2007, 77, 649-658.	1.8	150
16	Treatments targeting inotropy. <i>European Heart Journal</i> , 2019, 40, 3626-3644.	1.0	123
17	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. <i>European Journal of Heart Failure</i> , 2018, 20, 445-459.	2.9	118
18	Human myocytes are protected from titin aggregation-induced stiffening by small heat shock proteins. <i>Journal of Cell Biology</i> , 2014, 204, 187-202.	2.3	98

#	ARTICLE	IF	CITATIONS
19	Absence of Thrombospondin-2 Causes Age-Related Dilated Cardiomyopathy. <i>Circulation</i> , 2009, 120, 1585-1597.	1.6	92
20	Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. <i>Cardiovascular Research</i> , 2018, 114, 1287-1303.	1.8	91
21	Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function. <i>Cardiovascular Research</i> , 2021, 117, 43-59.	1.8	72
22	Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond. <i>European Journal of Heart Failure</i> , 2019, 21, 14-22.	2.9	71
23	Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. <i>Cardiovascular Research</i> , 2014, 104, 423-431.	1.8	70
24	A porcine model of hypertensive cardiomyopathy: implications for heart failure with preserved ejection fraction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 309, H1407-H1418.	1.5	70
25	Lack of specificity of antibodies directed against human beta-adrenergic receptors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2009, 379, 403-407.	1.4	69
26	Myofilament dysfunction in cardiac disease from mice to men. <i>Journal of Muscle Research and Cell Motility</i> , 2008, 29, 189-201.	0.9	67
27	Tampering with springs: phosphorylation of titin affecting the mechanical function of cardiomyocytes. <i>Biophysical Reviews</i> , 2017, 9, 225-237.	1.5	65
28	Diabetes-Induced Cardiomyocyte Passive Stiffening Is Caused by Impaired Insulin-Dependent Titin Modification and Can Be Modulated by Neuregulin-1. <i>Circulation Research</i> , 2018, 123, 342-355.	2.0	64
29	Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. <i>Cardiovascular Research</i> , 2018, 114, 1273-1280.	1.8	64
30	Aging-regulated anti-apoptotic long non-coding RNA Sarrah augments recovery from acute myocardial infarction. <i>Nature Communications</i> , 2020, 11, 2039.	5.8	63
31	Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis. <i>Basic Research in Cardiology</i> , 2014, 109, 449.	2.5	55
32	Increased passive stiffness promotes diastolic dysfunction despite improved Ca <sup>2+</sup> handling during left ventricular concentric hypertrophy. <i>Cardiovascular Research</i> , 2017, 113, 1161-1172.	1.8	54
33	Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 167, 17-31.	0.9	52
34	Sphingosine-1-Phosphate Receptor 1 Regulates Cardiac Function by Modulating Ca <sup>2+</sup> Sensitivity and Na <sup>+</sup> /H <sup>+</sup> Exchange and Mediates Protection by Ischemic Preconditioning. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	51
35	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2020, 116, 1820-1834.	1.8	51
36	Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. <i>European Heart Journal</i> , 2009, 30, 1863-1872.	1.0	50

#	ARTICLE	IF	CITATIONS
37	Mode-of-action of the PROPELLA concept in fulminant myocarditis. <i>European Heart Journal</i> , 2019, 40, 2164-2169.	1.0	49
38	Intercellular communication lessons in heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 1091-1103.	2.9	47
39	The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases. <i>Biophysical Reviews</i> , 2020, 12, 947-968.	1.5	47
40	Protein phosphatase 5 regulates titin phosphorylation and function at a sarcomere-associated mechanosensor complex in cardiomyocytes. <i>Nature Communications</i> , 2018, 9, 262.	5.8	44
41	SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?. <i>Current Heart Failure Reports</i> , 2021, 18, 315-328.	1.3	43
42	Cardiac contractility modulation signals improve exercise intolerance and maladaptive regulation of cardiac key proteins for systolic and diastolic function in HFpEF. <i>International Journal of Cardiology</i> , 2016, 203, 1061-1066.	0.8	42
43	Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2020, 116, 1805-1819.	1.8	39
44	Regulation of titin-based cardiac stiffness by unfolded domain oxidation (UnDOx). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24545-24556.	3.3	37
45	Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. <i>European Heart Journal</i> , 2021, 42, 1940-1958.	1.0	34
46	Effects of Atrial Fibrillation on the Human Ventricle. <i>Circulation Research</i> , 2022, 130, 994-1010.	2.0	32
47	Modulation of Titin-Based Stiffness in Hypertrophic Cardiomyopathy via Protein Kinase D. <i>Frontiers in Physiology</i> , 2020, 11, 240.	1.3	31
48	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2022, 118, 3016-3051.	1.8	30
49	From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. <i>Heart</i> , 2016, 102, 320-330.	1.2	29
50	Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator. <i>Frontiers in Physiology</i> , 2020, 11, 345.	1.3	29
51	A change of heart: oxidative stress in governing muscle function?. <i>Biophysical Reviews</i> , 2015, 7, 321-341.	1.5	28
52	Placenta-Derived Adherent Stromal Cells Improve Diabetes Mellitus-Associated Left Ventricular Diastolic Performance. <i>Stem Cells Translational Medicine</i> , 2017, 6, 2135-2145.	1.6	28
53	CX3CR1 knockout aggravates Coxsackievirus B3-induced myocarditis. <i>PLoS ONE</i> , 2017, 12, e0182643.	1.1	28
54	Diastolic dysfunction is initiated by cardiomyocyte impairment ahead of endothelial dysfunction due to increased oxidative stress and inflammation in an experimental prediabetes model. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 137, 119-131.	0.9	27

#	ARTICLE	IF	CITATIONS
55	Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function. <i>Cardiovascular Research</i> , 2021, 117, 2416-2433.	1.8	27
56	C-type natriuretic peptide moderates titin-based cardiomyocyte stiffness. <i>JCI Insight</i> , 2020, 5, .	2.3	25
57	CaMKII activity contributes to homeometric autoregulation of the heart: A novel mechanism for the Anrep effect. <i>Journal of Physiology</i> , 2020, 598, 3129-3153.	1.3	23
58	Î±-B Crystallin Reverses High Diastolic Stiffness of Failing Human Cardiomyocytes. <i>Circulation: Heart Failure</i> , 2017, 10, e003626.	1.6	20
59	Early myocardial changes induced by doxorubicin in the nonfailing dilated ventricle. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 316, H459-H475.	1.5	19
60	Stretch-induced compliance: a novel adaptive biological mechanism following acute cardiac load. <i>Cardiovascular Research</i> , 2018, 114, 656-667.	1.8	18
61	The Interplay between S-Glutathionylation and Phosphorylation of Cardiac Troponin I and Myosin Binding Protein C in End-Stage Human Failing Hearts. <i>Antioxidants</i> , 2021, 10, 1134.	2.2	16
62	Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIAâ€HFpEF trial. <i>ESC Heart Failure</i> , 2020, 7, 4478-4487.	1.4	15
63	Stress activated signalling impaired protein quality control pathways in human hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2021, 344, 160-169.	0.8	15
64	Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	13
65	Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Physiology</i> , 2021, 12, 752370.	1.3	12
66	Molecular and pathophysiological links between heart failure with preserved ejection fraction and type 2 diabetes mellitus. <i>European Journal of Heart Failure</i> , 2018, 20, 1649-1652.	2.9	11
67	Characterization of biventricular alterations in myocardial (reverse) remodelling in aortic banding-induced chronic pressure overload. <i>Scientific Reports</i> , 2019, 9, 2956.	1.6	11
68	Regression of left ventricular hypertrophy with SGLT2 inhibitors. <i>European Heart Journal</i> , 2020, 41, 3433-3436.	1.0	11
69	Long-term effects of empagliflozin on excitation-contraction-coupling in human induced pluripotent stem cell cardiomyocytes. <i>Journal of Molecular Medicine</i> , 2020, 98, 1689-1700.	1.7	10
70	Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischaemic injury: a translational study. <i>Cardiovascular Research</i> , 2023, 118, 3374-3385.	1.8	10
71	SARS-CoV-2 infects human cardiomyocytes promoted by inflammation and oxidative stress. <i>International Journal of Cardiology</i> , 2022, 362, 196-205.	0.8	9
72	Treatment of Heart Failure With Normal Ejection Fraction. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2011, 13, 26-34.	0.4	8

#	ARTICLE	IF	CITATIONS
73	MALDI-MS as a Tool to Determine the Myocardial Response to Syndecan-2-Selected Mesenchymal Stromal Cell Application in an Experimental Model of Diabetic Cardiomyopathy. <i>Proteomics - Clinical Applications</i> , 2021, 15, e2000050.	0.8	8
74	De Novo Missense Mutations in TNNC1 and TNNI3 Causing Severe Infantile Cardiomyopathy Affect Myofilament Structure and Function and Are Modulated by Troponin Targeting Agents. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9625.	1.8	8
75	Acute stimulation of the soluble guanylate cyclase does not impact on left ventricular capacitance in normal and hypertrophied porcine hearts in vivo. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H669-H680.	1.5	6
76	Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy. <i>Journal of Translational Medicine</i> , 2020, 18, 470.	1.8	6
77	Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 729-741.	1.6	6
78	Interventricular Differences of Signaling Pathways-Mediated Regulation of Cardiomyocyte Function in Response to High Oxidative Stress in the Post-Ischemic Failing Rat Heart. <i>Antioxidants</i> , 2021, 10, 964.	2.2	5
79	Integration of Cardiac Actin Mutants Causing Hypertrophic (p.A295S) and Dilated Cardiomyopathy (p.R312H and p.E361G) into Cellular Structures. <i>Antioxidants</i> , 2021, 10, 1082.	2.2	5
80	Alteration of the beta-adrenergic signaling pathway in human heart failure. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 2522-31.	0.9	5
81	Ca <sup>2+</sup> /calmodulin-dependent protein kinase II and protein kinase G oxidation contributes to impaired sarcomeric proteins in hypertrophy model. <i>ESC Heart Failure</i> , 2022, 9, 2585-2600.	1.4	5
82	A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article "Baseline characteristics of patients with heart failure with preserved ejection fraction in the <sc>EMPEROR</sc> Preserved trial". <i>European Journal of Heart Failure</i> , 2021, 23, 841-841.	2.9	4
83	Impact of Syndecan-2-Selected Mesenchymal Stromal Cells on the Early Onset of Diabetic Cardiomyopathy in Diabetic db/db Mice. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 632728.	1.1	4
84	Cardiomyocyte Dysfunction in Inherited Cardiomyopathies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11154.	1.8	3
85	Nicotinic acid derivative BGP-15 improves diastolic function in a rabbit model of atherosclerotic cardiomyopathy. <i>British Journal of Pharmacology</i> , 2022, 179, 2240-2258.	2.7	3
86	Functional Characterization of Cardiac Actin Mutants Causing Hypertrophic (p.A295S) and Dilated Cardiomyopathy (p.R312H and p.E361G). <i>International Journal of Molecular Sciences</i> , 2022, 23, 4465.	1.8	3
87	Response to Letter Regarding Article, "Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension". <i>Circulation</i> , 2008, 117, .	1.6	2
88	Increased nitrosative/oxidative stress lowers myocardial protein kinase G activity in heart failure with preserved ejection fraction. <i>BMC Pharmacology &amp; Toxicology</i> , 2013, 14, .	1.0	2
89	Impact of cGMP-PKG Pathway Modulation on Titin Phosphorylation and Titin-Based Myocardial Passive Stiffness. <i>Biophysical Journal</i> , 2016, 110, 526a.	0.2	1
90	Do they come together? Protein quality control, stress-activated signaling, and "sarcostatin" in hypertrophic cardiomyopathy progression. <i>International Journal of Cardiology</i> , 2022, 347, 44-45.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Myocardial Titin: An Important Modifier of Cardiac Stiffness. <i>Biophysical Journal</i> , 2014, 106, 346a.	0.2	0
92	Small Heat Shock Proteins Prevent Titin Aggregation-Induced Stiffening in Human Myocytes. <i>Biophysical Journal</i> , 2014, 106, 160a.	0.2	0
93	Large-Scale Modulation of Titin Elasticity by S-Glutathionylation of Cryptic Cysteines. <i>Biophysical Journal</i> , 2014, 106, 454a.	0.2	0
94	Oxidative Stress Regulates Titin Elasticity by Affecting Ig-Domain Stability. <i>Biophysical Journal</i> , 2015, 108, 444a.	0.2	0
95	A Novel Role for PP5 in Regulating Titin Phosphorylation and Function in the Heart. <i>Biophysical Journal</i> , 2016, 110, 298a.	0.2	0
96	Impact of cGMP-PKG Pathway Modulation on Titin Phosphorylation and Titin-Based Myocardial Passive Stiffness. <i>Biophysical Journal</i> , 2017, 112, 257a.	0.2	0
97	Cardiac transcriptomic remodeling in metabolic syndrome. , 2021, , 187-211.		0
98	Human myocytes are protected from titin aggregation-induced stiffening by small heat shock proteins. <i>Journal of General Physiology</i> , 2014, 143, 1432OIA1.	0.9	0
99	Abstract 210: Titin Phosphorylation by Protein Kinase G as a Novel Mechanism of Diastolic Adaptation to Acute Hemodynamic Overload. <i>Circulation Research</i> , 2015, 117, .	2.0	0
100	The PDE9A inhibitor PF04447943 improves coronary arteriole vasodilation and left ventricular diastolic dysfunction in HFpEF. <i>FASEB Journal</i> , 2019, 33, 693.10.	0.2	0
101	Abstract 10973: Tenascin-C Deficiency Rescues the Effect of Diabetes on Cardiac and Vascular Dysfunction in Mice. <i>Circulation</i> , 2021, 144, .	1.6	0
102	Abstract 10477: Targeting the Methyltransferase Setd7 Prevents Myocardial Ischemic Injury: A Translational Study. <i>Circulation</i> , 2021, 144, .	1.6	0